A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
Insights into the BZKF BORN-Project – Interview with Dr. Mandy Wahlbuhl-Becker
The Bavarian Oncological Radiology Network (BORN) is enhancing cancer diagnostics in Bavaria through standardized imaging and structured reporting. …
The Bavarian Oncological Radiology Network – Standardized Imaging for Improved Cancer Care: Interview with Dr. Mandy Wahlbuhl-Becker
The Bavarian Oncological Radiology Network (BORN) aims to support patients and medical professionals across Bavaria by standardizing imaging…
RACOON-RESCUE is Advancing Pediatric Non-Hodgkin Lymphoma Care
Pediatric Non-Hodgkin Lymphoma (NHL) is the fourth most common tumor in children and adolescents, yet its radiological methods lack standardization,…